Bosutinib
Price | USD5.00 |
Packge | 5KG |
- Min. Order:1KG
- Supply Ability:1ton
- Time:2019-09-04
Product Details
- Product NameBosutinib
- CAS No.380843-75-4
- EINECS No.200-256-5
- MFC26H29Cl2N5O3
- MW530.45
- Appearancepowderoff-white to light brown
- density 1.36
- Melting point 116-120 ºC
- storage temp. room temp
- Boiling point 649.7±55.0 °C(Predicted)
▼
▲
Bosutinib Basic information
▼
▲
Product Name:
Synonyms:
3-Quinolinecarbonitrile, 4-[(2,4-dichloro-5-Methoxyphenyl)aMino]-6-Methoxy-7-[3-(4-Methyl-1-piperazinyl)propoxy]-;Bosutinib(TINIBS );4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile Bosutinib (SKI-606);WAY-173606;Bosulif(bosutinib);SKI-606;SKI 606 - Bosutinib;4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile
CAS:
MF:
C26H29Cl2N5O3
MW:
530.45
EINECS:
700-455-1
Product Categories:
Mol File:
▼
▲
Bosutinib Chemical Properties
▼
▲
Melting point
116-120 ºC
density
1.36
storage temp.
room temp
solubility
DMSO: ≥15mg/mL
form
powder
color
off-white to light brown
CAS DataBase Reference
▼
▲
Safety Information
▼
▲
Bosutinib Usage And Synthesis
▼
▲
Description
In September 2012, the US FDA approved bosutinib (also referred to as SKI-607) for the treatment of relapsed or refractory chronicmyeloid leukemia (CML) for patients with resistance or intolerance to prior therapy. The National Cancer Institute estimates that in 2012, 5430 men and women were diagnosed with CML and 610 died of CML. First and second-line therapies for the treatment of CML include imatinib, dasatinib, and nilotinib. Bosutinib, which was initially identified as a Src inhibitor, was later found to be a dual inhibitor of Bcr–Abl (IC50=1.4 nM) and Src family kinases (IC50=3.5 nM). Bosutinib inhibits 16 of 18 imatinib-resistant forms of Bcr–Abl expressed in murine myeloid cell lines. In preclinical in vivo studies, bosutinib at 15 mg/kg administered orally for 5 days caused regression of K562 CML tumors in nude mice and in BaF3 tumors expressing wild type or different imatinib-resistant Bcr–Abl mutants at varying doses. A manufacturing process for the synthesis of bosutinib monohydrate has been reported that employs a key three-component cyclization reaction involving an aniline, a cyanoacetamide intermediate, and triethyl orthoformate followed by cyclization using phosphorous oxytrichloride and an optimized hydration procedure.
Chemical Properties
Pale Yellow Solid
Originator
Wyeth (United States)
Uses
Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM, respectively.
Uses
A novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.
Uses
peripheral vasolidator increases cerebral blood flow, potential therapeutic for Altzheimer’s disease, cognitive impairment and dementia
Definition
ChEBI: An aminoquinoline that is 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline bearing additional cyano and methoxy substituents at positions 3 and 6 respectively.
Brand name
Bosulif
Company Profile Introduction
Established in 2014,Career Henan Chemical Co. is a manufacturerspecializing in the sale of fine chemicals.
Mainly deals in the sales of:
Pharmaceutical intermediates
OLED intermediates:
Pharmaceutical intermediates;
OLED intermediates;
Recommended supplier
-
VIP1年
- SETV ASRV LLP
- 380843-75-4 BOSUTINIB 95-99%
- Inquiry
- 2024-09-11
-
VIP1年
- Brawn Laboratories Limited
- 380843-75-4 99%
- Inquiry
- 2024-02-05
-
VIP2年
- AVD pharmaceuticals Pvt Ltd
- 380843-75-4 Bosutinib 98%
- Inquiry
- 2023-09-11
- Since:2014-12-17
- Address: No.967,15th Floor,Unit 7, Building 1, No.70 of DianChang Road, High-tech Development Zone, Zhengzho
INQUIRY